Insulet Corporation (NASDAQ: PODD) is a global healthcare company dedicated to creating innovative medical devices to improve the lives of people with diabetes and other conditions. Initiated in 2000 and headquartered in Acton, Massachusetts, Insulet Corporation is well recognized for its development, manufacture, and distribution of insulin delivery systems for people with insulin-dependent diabetes.
Insulet's primary product, the Omnipod Insulin Management System, is a unique, automated drug delivery platform that provides several significant advantages such as the ability to eliminate the burden of daily injections. It allows users to manage diabetes by delivering precise doses of insulin when needed. The initiative behind the Omnipod system was to offer a practical, full-featured insulin pump that's easy to use, with no tubes and a long-life sensory design that provides users with the freedom to live their lives with ease.
Moreover, Insulet Corp expanded its horizons by developing the Omnipod DASH system, which integrates a tubeless, waterproof insulin pump with modern touchscreen Personal Diabetes Manager (PDM). The DASH features Bluetooth wireless technology that enables connectivity to mobile devices, streamlining diabetes management for its users.
In addition to the revolutionary Omnipod Systems, Insulet Corporation offers other innovative solutions, including the Omnipod HORIZON System – an innovative, secure, and efficient hybrid closed-loop system.
The effectiveness of Insulet Corporation's approach reflects in its financial performance. Over the years, the organization has expanded its customer base to tens of thousands of individuals globally. Its revenue has grown exponentially, with year-over-year revenue growth frequently outpacing the industry average.
Insulet Corporation's commitment goes beyond creating innovative medical devices. It involves a mission to make a difference in the lives of individuals with diabetes, working to reduce its impacts and improve their quality of life. This commitment drives scientific research and investment in new technologies to ease the burden of diabetes management.
Furthermore, Insulet Corp values sustainability and commits to environmental, social, and governance principles, demonstrating ethical corporate citizenship. For example, the company takes steps to reduce the environmental impact of its operations and products.
In conclusion, Insulet Corporation is more than just a medical devices company. It is a pioneer in the field of diabetes management, with a solid reputation for delivering ground-breaking products that enhance and simplify the lives of people dealing with diabetes internationally. Insulet Corporation truly stands out for its innovative approach, dedication to improving patients' lives, and commitment to social responsibility.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
This article analyzes Insulet Corporation (NASDAQ: PODD) using AI models, identifying strong near and mid-term sentiment but a weak long-term outlook. It presents three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis also highlights support and resistance levels across different time horizons for informed decision-making.
Insulet Corp. (PODD) stock rose 2.40% to $152.50 on Thursday, despite a broader market downturn where the S&P 500 Index and Dow Jones Industrial Average both fell. The company's stock closed 57.03% below its 52-week high of $354.88 achieved on November 20th. This performance indicates that Insulet Corp. underperformed relative to its competitors even with daily gains.
Beta Bionics reported Q3 2026 net sales of $35.5 million, a 30% year-over-year growth, and received FDA clearance for Mint, a new patch pump set to launch in Q1 2027. The company raised $161 million to support Mint's commercialization and updated its full-year 2026 revenue guidance to $124-$126 million. They are also progressing with new algorithm developments and a pivotal trial for a fully closed-loop system, despite a temporary withdrawal and resubmission of their 3D Intelligence algorithm to the FDA.